Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × anlotinib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 6 Thyroid Neoplasms 2 Nasopharyngeal Carcinoma 2 Whole-Brain Radiotherapy 1 Triple Negative Breast Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Progression Free Survival(PFS) 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Fulvestrant 64 Paclitaxel 56 Letrozole 55 Trastuzumab 51 pembrolizumab 46 Capecitabine 37 ribociclib 36 palbociclib 36 pertuzumab 34 Tamoxifen 34 Anastrozole 34 abemaciclib 33 exemestane 31 Cyclophosphamide 30 Specimen Handling 29 Carboplatin 29 trastuzumab deruxtecan 27 Surveys and Questionnaires 23 Blood Specimen Collection 23 Radiotherapy 22 olaparib 21 Magnetic Resonance Spectroscopy 21 Biopsy 19 Mastectomy, Segmental 17 130-nm albumin-bound paclitaxel 17 Doxorubicin 16 eribulin 15 Standard of Care 15 Ado-Trastuzumab Emtansine 15 Gemcitabine 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07520760 2026-04-09

MBC-EA

Sun Yat-sen University

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡